A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive Mutation

NCT03420079 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: FCN-411 Dose-escalation
DRUG: FCN-411 Dose-expansion

Sponsor

Ahon Pharmaceutical Co., Ltd.

Collaborators

[object Object]